T1	CHEM 24 35	pregabalina
#1	AnnotatorNotes T1	C0657912; pregabalin; Amino Acid, Peptide, or Protein · Pharmacologic Substance
T2	CHEM 47 57	analgésico
#2	AnnotatorNotes T2	C0002771; Analgesics; Organic Chemical · Pharmacologic Substance · Hazardous or Poisonous Substance
T3	CHEM 244 259	gabapentinoides
T4	CHEM 100 108	opiáceos
#3	AnnotatorNotes T4	C0242402; Opioids; Hazardous or Poisonous Substance · Organic Chemical · Pharmacologic Substance | C0376196; Opiates; Hazardous or Poisonous Substance · Organic Chemical · Pharmacologic Substance
T5	PROC 134 159	nefrolitotomía percutánea
#4	AnnotatorNotes T5	C0162428; Nephrolithotomy, Percutaneous; Therapeutic or Preventive Procedure
T6	CHEM 210 233	medicamentos adyuvantes
T7	CHEM 272 282	analgésico
#5	AnnotatorNotes T7	C0002771; Analgesics; Organic Chemical · Pharmacologic Substance · Hazardous or Poisonous Substance
T8	PROC 264 293	régimen analgésico multimodal
T9	CHEM 405 413	opiáceos
#6	AnnotatorNotes T9	C0242402; Opioids; Hazardous or Poisonous Substance · Organic Chemical · Pharmacologic Substance | C0376196; Opiates; Hazardous or Poisonous Substance · Organic Chemical · Pharmacologic Substance
T10	PROC 454 479	nefrolitotomía percutánea
#7	AnnotatorNotes T10	C0162428; Nephrolithotomy, Percutaneous; Therapeutic or Preventive Procedure
T11	PROC 2273 2297	administrada precozmente
T12	CHEM 562 573	pregabalina
#8	AnnotatorNotes T12	C0657912; pregabalin; Amino Acid, Peptide, or Protein · Pharmacologic Substance
T13	CHEM 615 626	analgésicos
#9	AnnotatorNotes T13	C0002771; Analgesics; Organic Chemical · Pharmacologic Substance · Hazardous or Poisonous Substance
T14	PROC 662 688	aclaramiento de creatinina
#10	AnnotatorNotes T14	C0373595; Creatinine clearance measurement; Laboratory Procedure
T15	ANAT 699 706	séricos
#11	AnnotatorNotes T15	C0229671; Serum; Body Substance | C0588987; Serum product; Body Substance
T16	ANAT 765 776	neutrófilos
#12	AnnotatorNotes T16	C0027950; neutrophil; Cell
T17	PROC 805 830	nefrolitotomía percutánea
#13	AnnotatorNotes T17	C0162428; Nephrolithotomy, Percutaneous; Therapeutic or Preventive Procedure
T18	PROC 873 898	nefrolitotomía percutánea
#14	AnnotatorNotes T18	C0162428; Nephrolithotomy, Percutaneous; Therapeutic or Preventive Procedure
T19	CHEM 988 999	pregabalina
#15	AnnotatorNotes T19	C0657912; pregabalin; Amino Acid, Peptide, or Protein · Pharmacologic Substance
T20	CHEM 1247 1257	gelatinasa
#16	AnnotatorNotes T20	C0206528; Gelatinases; Amino Acid, Peptide, or Protein · Enzyme
T21	CHEM 1036 1047	pregabalina
#17	AnnotatorNotes T21	C0657912; pregabalin; Amino Acid, Peptide, or Protein · Pharmacologic Substance
T22	CHEM 1222 1232	lipocalina
#18	AnnotatorNotes T22	C0078147; lipocalin 1; Amino Acid, Peptide, or Protein · Pharmacologic Substance
T23	PROC 1107 1130	escala visual analógica
#19	AnnotatorNotes T23	C0042815; Visual Analog Pain Scale; Diagnostic Procedure | C2959685; Assessment using visual analog scale; Health Care Activity
T24	CHEM 1146 1153	morfina
#20	AnnotatorNotes T24	C0026549; morphine; Organic Chemical · Pharmacologic Substance
T25	ANAT 1212 1218	sérico
#21	AnnotatorNotes T25	C0229671; Serum; Body Substance | C0588987; Serum product; Body Substance
T26	ANAT 1261 1272	neutrófilos
#22	AnnotatorNotes T26	C0027950; neutrophil; Cell
T27	PROC 1299 1325	aclaramiento de creatinina
#23	AnnotatorNotes T27	C0373595; Creatinine clearance measurement; Laboratory Procedure
T28	PROC 2046 2107	niveles de lipocalina asociada a la gelatinasa de neutrófilos
#24	AnnotatorNotes T28	C5202571; Neutrophil gelatinase-associated lipocalin; Laboratory Procedure
T29	PROC 1443 1466	escala visual analógica
#25	AnnotatorNotes T29	C0042815; Visual Analog Pain Scale; Diagnostic Procedure | C2959685; Assessment using visual analog scale; Health Care Activity
T30	CHEM 1534 1545	pregabalina
#26	AnnotatorNotes T30	C0657912; pregabalin; Amino Acid, Peptide, or Protein · Pharmacologic Substance
T31	CHEM 1648 1655	morfina
#27	AnnotatorNotes T31	C0026549; morphine; Organic Chemical · Pharmacologic Substance
T32	CHEM 1766 1777	pregabalina
#28	AnnotatorNotes T32	C0657912; pregabalin; Amino Acid, Peptide, or Protein · Pharmacologic Substance
T33	PROC 1936 1962	aclaramiento de creatinina
#29	AnnotatorNotes T33	C0373595; Creatinine clearance measurement; Laboratory Procedure
T34	PROC 1965 1976	cistatina-C
#30	AnnotatorNotes T34	C1619716; Cystatin C measurement; Laboratory Procedure
T35	ANAT 2096 2107	neutrófilos
#31	AnnotatorNotes T35	C0027950; neutrophil; Cell
T36	CHEM 2188 2199	pregabalina
#32	AnnotatorNotes T36	C0657912; pregabalin; Amino Acid, Peptide, or Protein · Pharmacologic Substance
T37	CHEM 2256 2267	pregabalina
#33	AnnotatorNotes T37	C0657912; pregabalin; Amino Acid, Peptide, or Protein · Pharmacologic Substance
T38	DISO 2511 2530	efectos colaterales
#34	AnnotatorNotes T38	C0879626; Adverse effects; Pathologic Function
T39	CHEM 2407 2418	analgésicos
#35	AnnotatorNotes T39	C0002771; Analgesics; Organic Chemical · Pharmacologic Substance · Hazardous or Poisonous Substance
T40	PROC 2444 2469	nefrolitotomía percutánea
#36	AnnotatorNotes T40	C0162428; Nephrolithotomy, Percutaneous; Therapeutic or Preventive Procedure
T41	DISO 2482 2508	inestabilidad hemodinámica
#37	AnnotatorNotes T41	C0948268; Hemodynamic instability; Disease or Syndrome
T42	PROC 39 57	régimen analgésico
#38	AnnotatorNotes T42	C0262176; Administration of analgesic; Therapeutic or Preventive Procedure (?)
T43	DISO 420 439	efectos colaterales
#39	AnnotatorNotes T43	C0879626; Adverse effects; Pathologic Function
T44	DISO 81 86	dolor
#40	AnnotatorNotes T44	C0030193; Pain; Sign or Symptom | C0234238; Ache; Sign or Symptom
T45	PROC 691 721	niveles séricos de cistatina-C
#41	AnnotatorNotes T45	C1319318; Serum cystatin C measurement; Laboratory Procedure
T46	CHEM 710 721	cistatina-C
#42	AnnotatorNotes T46	C0071744; Cystatin C (substance); Amino Acid, Peptide, or Protein · Pharmacologic Substance
T47	DISO 357 362	dolor
#43	AnnotatorNotes T47	C0030193; Pain; Sign or Symptom | C0234238; Ache; Sign or Symptom
T48	DISO 597 602	dolor
#44	AnnotatorNotes T48	C0030193; Pain; Sign or Symptom | C0234238; Ache; Sign or Symptom
T49	CHEM 724 734	lipocalina
#45	AnnotatorNotes T49	C0078147; lipocalin 1; Amino Acid, Peptide, or Protein · Pharmacologic Substance
T50	ANAT 639 646	renales
#46	AnnotatorNotes T50	C0022646; Kidney; Body Part, Organ, or Organ Component | C1278978; Entire kidney; Body Part, Organ, or Organ Component
T51	CHEM 678 688	creatinina
#47	AnnotatorNotes T51	C0010294; creatinine; Organic Chemical · Biologically Active Substance
T52	DISO 1086 1091	dolor
#48	AnnotatorNotes T52	C0030193; Pain; Sign or Symptom | C0234238; Ache; Sign or Symptom
T53	CHEM 1315 1325	creatinina
#49	AnnotatorNotes T53	C0010294; creatinine; Organic Chemical · Biologically Active Substance
T54	CHEM 1952 1962	creatinina
#50	AnnotatorNotes T54	C0010294; creatinine; Organic Chemical · Biologically Active Substance
T55	DISO 2348 2353	dolor
#51	AnnotatorNotes T55	C0030193; Pain; Sign or Symptom | C0234238; Ache; Sign or Symptom
T56	CHEM 751 761	gelatinasa
#52	AnnotatorNotes T56	C0206528; Gelatinases; Amino Acid, Peptide, or Protein · Enzyme
T57	PROC 724 776	lipocalina asociada con la gelatinasa de neutrófilos
#53	AnnotatorNotes T57	C5202571; Neutrophil gelatinase-associated lipocalin; Laboratory Procedure
T58	PROC 961 974	aleatorizados
#54	AnnotatorNotes T58	C0034656; Randomization; Research Activity
T59	PROC 1206 1272	nivel sérico de lipocalina asociada a la gelatinasa de neutrófilos
T60	PROC 1274 1296	niveles de cistatina-C
#55	AnnotatorNotes T60	C1619716; Cystatin C measurement; Laboratory Procedure
T61	CHEM 1285 1296	cistatina-C
#56	AnnotatorNotes T61	C0071744; Cystatin C (substance); Amino Acid, Peptide, or Protein · Pharmacologic Substance
T62	CHEM 2057 2067	lipocalina
#57	AnnotatorNotes T62	C0078147; lipocalin 1; Amino Acid, Peptide, or Protein · Pharmacologic Substance
T63	CHEM 2082 2092	gelatinasa
#58	AnnotatorNotes T63	C0206528; Gelatinases; Amino Acid, Peptide, or Protein · Enzyme
T64	Dose 15 20	75 mg
T66	LIVB 112 119	adultos
#59	AnnotatorNotes T66	C0001675; Adult; Age Group
T70	Time 369 383	postoperatorio
#60	AnnotatorNotes T70	C0032790; Postoperative Period; Temporal Concept
T71	Time 522 544	período postoperatorio
#61	AnnotatorNotes T71	C0032790; Postoperative Period; Temporal Concept
T73	LIVB 780 789	pacientes
#62	AnnotatorNotes T73	C0030705; Patients; Patient or Disabled Group
T74	LIVB 851 860	pacientes
#63	AnnotatorNotes T74	C0030705; Patients; Patient or Disabled Group
T75	LIVB 944 953	pacientes
#64	AnnotatorNotes T75	C0030705; Patients; Patient or Disabled Group
T76	Route 1000 1004	oral
#65	AnnotatorNotes T76	C1527415; Oral Route of Drug administration; Functional Concept
T77	Dose 1008 1028	dosis única de 75 mg
T79	LIVB 1051 1064	grupo control
#66	AnnotatorNotes T79	C0009932; Control Groups; Group
T81	Route 1154 1165	intravenosa
#67	AnnotatorNotes T81	C1522726; Intravenous Route of Drug Administration; Functional Concept
T83	Duration 1169 1186	las primeras 24 h
T84	Time 1347 1360	preoperatorio
#68	AnnotatorNotes T84	C0445204; Preoperative; Temporal Concept | C2712277; Preoperative Period; Temporal Concept
T86	Time 1473 1487	postoperatorio
#69	AnnotatorNotes T86	C0032790; Postoperative Period; Temporal Concept
T87	Duration 1548 1558	los 30 min
T88	Duration 1560 1567	1 y 2 h
T89	Time 1662 1676	postoperatorio
#70	AnnotatorNotes T89	C0032790; Postoperative Period; Temporal Concept
T91	Time 1983 1996	preoperatorio
#71	AnnotatorNotes T91	C0445204; Preoperative; Temporal Concept | C2712277; Preoperative Period; Temporal Concept
T92	Duration 2002 2021	la 2.a y 24.a horas
T93	Duration 2111 2122	la 24.ahora
T95	Dose 2232 2252	dosis única de 75 mg
T96	Route 2268 2272	oral
#72	AnnotatorNotes T96	C1527415; Oral Route of Drug administration; Functional Concept
T98	Time 2360 2374	postoperatorio
#73	AnnotatorNotes T98	C0032790; Postoperative Period; Temporal Concept
T99	LIVB 2422 2431	pacientes
#74	AnnotatorNotes T99	C0030705; Patients; Patient or Disabled Group
T100	Neg_cue 2471 2474	sin
T101	PHYS 2496 2508	hemodinámica
#75	AnnotatorNotes T101	C0019010; Hemodynamics; Organ or Tissue Function
T102	PHYS 629 646	funciones renales
#76	AnnotatorNotes T102	C0232804; Renal function; Organ or Tissue Function
T65	Duration 1366 1385	la 2.a y 24.a horas
T67	Time 2127 2141	postoperatorio
#77	AnnotatorNotes T67	C0032790; Postoperative Period; Temporal Concept
T68	Time 2026 2040	postoperatorio
#78	AnnotatorNotes T68	C0032790; Postoperative Period; Temporal Concept
T69	Time 1190 1204	postoperatorio
#79	AnnotatorNotes T69	C0032790; Postoperative Period; Temporal Concept
T72	Time 1390 1404	postoperatorio
#80	AnnotatorNotes T72	C0032790; Postoperative Period; Temporal Concept
A1	Population_data T66 Age
A2	Assertion T41 Negated
A3	Assertion T38 Negated
R1	Negation Arg1:T100 Arg2:T41	
T78	Neg_cue 1851 1853	No
T80	CONC 1859 1869	diferencia
A4	Assertion T80 Negated
#81	AnnotatorNotes T80	C1705241; Delta (difference); Quantitative Concept
R2	Negation Arg1:T78 Arg2:T80	
R3	Has_Dose_or_Strength Arg1:T1 Arg2:T64	
R4	Used_for Arg1:T2 Arg2:T42	
R5	Used_for Arg1:T1 Arg2:T42	
T82	Observation 58 64;81 86	reduce dolor
#82	AnnotatorNotes T82	C5230944; Sensation of pain reduced; Finding
R6	Experiences Arg1:T66 Arg2:T44	
R7	Experiences Arg1:T66 Arg2:T4	
R8	Experiences Arg1:T66 Arg2:T5	
R9	Experiences Arg1:T66 Arg2:T82	
R10	Experiences Arg1:T66 Arg2:T1	
R11	Experiences Arg1:T66 Arg2:T42	
R12	Before Arg1:T1 Arg2:T5	
R13	Causes Arg1:T5 Arg2:T44	
T85	Observation 58 64;89 108	reduce consumo de opiáceos
R14	Experiences Arg1:T66 Arg2:T85	
R15	Causes Arg1:T1 Arg2:T85	
R16	Causes Arg1:T1 Arg2:T82	
#83	AnnotatorNotes T6	C0001552; Pharmaceutical Adjuvants; Chemical Viewed Functionally
R17	Used_for Arg1:T6 Arg2:T8	
R18	Used_for Arg1:T7 Arg2:T8	
R19	Used_for Arg1:T3 Arg2:T8	
T90	Observation 327 336;357 362	disminuir dolor
#84	AnnotatorNotes T90	C5230944; Sensation of pain reduced; Finding
R20	Overlap Arg1:T90 Arg2:T70	
R21	Causes Arg1:T3 Arg2:T90	
R22	Overlap Arg1:T47 Arg2:T70	
R23	After Arg1:T43 Arg2:T10	
R24	Before Arg1:T8 Arg2:T10	
T94	Observation 327 336;388 413	disminuir consumo total de opiáceos
R25	Causes Arg1:T3 Arg2:T94	
R26	After Arg1:T44 Arg2:T5	
R27	After Arg1:T85 Arg2:T5	
R28	After Arg1:T82 Arg2:T5	
R29	After Arg1:T94 Arg2:T10	
R30	After Arg1:T90 Arg2:T10	
R31	Causes Arg1:T10 Arg2:T47	
R32	Has_Dose_or_Strength Arg1:T37 Arg2:T95	
R33	Has_Route_or_Mode Arg1:T37 Arg2:T96	
R34	Used_for Arg1:T37 Arg2:T11	
T97	Observation 2315 2324;2345 2353	reducción de dolor
#85	AnnotatorNotes T97	C5230944; Sensation of pain reduced; Finding
R35	Overlap Arg1:T97 Arg2:T98	
R36	Overlap Arg1:T55 Arg2:T98	
R37	Causes Arg1:T37 Arg2:T97	
R38	Overlap Arg1:T37 Arg2:T40	
R39	Experiences Arg1:T99 Arg2:T40	
T103	Observation 2315 2327;2390 2418	reducción de consumo total de analgésicos
R40	Causes Arg1:T37 Arg2:T103	
R41	Experiences Arg1:T99 Arg2:T41	
R42	Experiences Arg1:T99 Arg2:T38	
R43	Negation Arg1:T100 Arg2:T38	
R44	Experiences Arg1:T99 Arg2:T101	
R45	Experiences Arg1:T99 Arg2:T37	
R46	Experiences Arg1:T99 Arg2:T97	
R47	Experiences Arg1:T99 Arg2:T103	
R48	Location_of Arg1:T50 Arg2:T102	
R49	Location_of Arg1:T15 Arg2:T45	
R50	Location_of Arg1:T16 Arg2:T57	
R51	Experiences Arg1:T73 Arg2:T17	
R52	Causes Arg1:T17 Arg2:T48	
R53	Before Arg1:T17 Arg2:T71	
R54	Overlap Arg1:T48 Arg2:T71	
R55	Experiences Arg1:T73 Arg2:T57	
R56	Experiences Arg1:T73 Arg2:T45	
R57	Experiences Arg1:T73 Arg2:T14	
R58	Experiences Arg1:T73 Arg2:T102	
R59	Experiences Arg1:T73 Arg2:T13	
R60	Experiences Arg1:T73 Arg2:T48	
R61	Experiences Arg1:T73 Arg2:T12	
R62	Experiences Arg1:T74 Arg2:T18	
T104	Quantifier_or_Qualifier 899 907	electiva
#86	AnnotatorNotes T104	C0439608; elective; Temporal Concept
R63	Has_Quantifier_or_Qualifier Arg1:T18 Arg2:T104	
R64	Before Arg1:T58 Arg2:T19	
R65	Before Arg1:T58 Arg2:T21	
R66	Experiences Arg1:T75 Arg2:T19	
R67	Has_Route_or_Mode Arg1:T19 Arg2:T76	
R68	Has_Dose_or_Strength Arg1:T19 Arg2:T77	
R69	Has_Dose_or_Strength Arg1:T21 Arg2:T77	
R70	Has_Route_or_Mode Arg1:T21 Arg2:T76	
R71	Experiences Arg1:T75 Arg2:T21	
R72	Has_Route_or_Mode Arg1:T24 Arg2:T81	
R73	Has_Duration_or_Interval Arg1:T24 Arg2:T83	
R74	Overlap Arg1:T24 Arg2:T69	
R75	Location_of Arg1:T25 Arg2:T59	
R76	Overlap Arg1:T27 Arg2:T84	
R77	Overlap Arg1:T60 Arg2:T84	
R78	Overlap Arg1:T59 Arg2:T84	
R79	Overlap Arg1:T23 Arg2:T84	
R80	Overlap Arg1:T52 Arg2:T69	
R81	Overlap Arg1:T52 Arg2:T72	
R82	Overlap Arg1:T52 Arg2:T65	
R83	Overlap Arg1:T27 Arg2:T65	
R84	Overlap Arg1:T60 Arg2:T65	
R85	Overlap Arg1:T59 Arg2:T65	
R86	Overlap Arg1:T23 Arg2:T65	
R87	Overlap Arg1:T23 Arg2:T72	
R88	Overlap Arg1:T27 Arg2:T72	
R89	Overlap Arg1:T60 Arg2:T72	
R90	Overlap Arg1:T59 Arg2:T72	
R91	Overlap Arg1:T29 Arg2:T86	
R92	Overlap Arg1:T29 Arg2:T87	
R95	Overlap Arg1:T29 Arg2:T88	
R96	Overlap Arg1:T31 Arg2:T89	
R98	Overlap Arg1:T34 Arg2:T91	
R99	Overlap Arg1:T33 Arg2:T91	
R100	Overlap Arg1:T33 Arg2:T92	
R101	Overlap Arg1:T34 Arg2:T92	
R102	Overlap Arg1:T34 Arg2:T68	
R103	Overlap Arg1:T33 Arg2:T68	
R104	Overlap Arg1:T28 Arg2:T93	
R105	Overlap Arg1:T28 Arg2:T67	
T105	Quantifier_or_Qualifier 2375 2384	inmediato
#87	AnnotatorNotes T105	C0205253; Immediate; Temporal Concept
R108	Has_Quantifier_or_Qualifier Arg1:T98 Arg2:T105	
T106	Observation 549 555	efecto
#88	AnnotatorNotes T106	C1518681; Outcome of Therapy; Finding (?)
R109	Causes Arg1:T12 Arg2:T106	
#89	AnnotatorNotes T11	C1964029; early/brief intervention/therapy (treatment); Therapeutic or Preventive Procedure
#90	AnnotatorNotes T59	C5202571; Neutrophil gelatinase-associated lipocalin; Laboratory Procedure (?)
A5	Experiencer T66 Patient
A6	Experiencer T73 Patient
A7	Experiencer T74 Patient
A8	Experiencer T75 Patient
A9	Experiencer T79 Patient
A10	Experiencer T99 Patient
